Momecutan (Mometasone Furoate Ph. Eur.)

Momecutan, a topical corticosteroid, is used to manage inflammatory skin disorders by reducing redness, scaling and itching.

• Psoriasis: decreases epidermal hyperplasia and inflammation, leading to reduced plaque thickness, scaling and erythema.
• Atopic dermatitis: alleviates itch and erythema, helping restore skin barrier function and reduce lesion spread.
• Seborrheic dermatitis: controls flaking, redness and irritation on scalp and facial areas, improving comfort.
• Contact dermatitis: reduces allergic and irritant reactions, minimizing swelling, redness and discomfort.

• Mometasone furoate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction suppresses pro‑inflammatory cytokine production, inhibits phospholipase A2 activity and reduces expression of adhesion molecules, leading to decreased inflammation, vasodilation and immune cell infiltration in the skin. Additionally, it down‑regulates inflammatory mediators such as prostaglandins and leukotrienes, contributing to its therapeutic effect.

Topical application of Momecutan may be associated with local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Burning sensation: transient warmth or stinging at the application site.
• Pruritus: mild itching that may occur after initial use.
• Dryness: skin may become dry or flaky.
• Erythema: mild redness of the treated area.
• Folliculitis: inflammation of hair follicles presenting as small pustules.

Serious or Rare Side Effects

• Skin atrophy: thinning of the skin with prolonged use.
• Telangiectasia: visible small blood vessels developing on the surface.
• Hypersensitivity reaction: rash, swelling or urticaria indicating allergy.
• Secondary infection: bacterial, fungal or viral infection of compromised skin.
• Systemic effects: adrenal suppression or Cushing‑like symptoms with extensive application.

When using Momecutan, certain precautions should be observed to minimize risks and ensure optimal therapeutic outcomes.

• Duration of use: limit continuous application to the shortest period required, typically not exceeding two weeks without medical review.
• Application area: avoid use on large body surface areas or under occlusive dressings unless directed.
• Age restrictions: use with caution in children under 2 years; pediatric dosing should follow specialist guidance.
• Pre‑existing conditions: assess for skin infections, tuberculosis or rosacea before initiating therapy.
• Concomitant steroids: avoid simultaneous use of other potent topical corticosteroids to reduce cumulative effects.
• Store at room temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Momecutan can interact with other agents applied to the skin or systemic medications that affect corticosteroid metabolism.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent systemic use may increase risk of adrenal suppression.
• CYP3A4 inhibitors: strong inhibitors (e.g., ketoconazole) can raise local steroid levels, enhancing side effects.
• Immunosuppressants: agents such as cyclosporine may heighten infection risk when combined.

Moderate Interactions (Monitor Closely)

• Antifungal or antibacterial topical agents: may alter skin barrier and affect absorption.
• Phototherapy: combined use can increase skin thinning risk.
• Non‑steroidal anti‑inflammatory drugs (topical): monitor for additive irritation.